{
  "questions": [
    {
      "id": "63f03006f36125a426000018",
      "type": "summary",
      "body": "What were the results of the DESTINY-Breast04 Trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
          "text": "CONCLUSIONS\nIn this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.",
          "offsetInBeginSection": 2191,
          "offsetInEndSection": 2414,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35665782"
      ]
    },
    {
      "id": "641ad941690f196b5100003d",
      "type": "yesno",
      "body": "Are LOQ and LOD the same?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
          "text": "of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here about the LOD/LOQ ",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1138,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
          "text": "The results indicated that the estimated LODs and LOQs were not equivalent and could vary by a factor of 5 to 6 for the different methods.",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 626,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
          "text": "Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
          "text": "Our conclusion is that the visual evaluation method provided much more realistic LOD and LOQ values.",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155649",
          "text": "The LOD and LOQ were in the ranges of 0.16-0.39 and 0.52-1.28\u00a0mg/kg, respectively.",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
        "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
        "http://www.ncbi.nlm.nih.gov/pubmed/28911409",
        "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155649"
      ]
    },
    {
      "id": "642a029d57b1c7a315000011",
      "type": "summary",
      "body": "Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
          "text": "ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
          "text": "The eukaryotic histone acetylation cycle is composed of three classes of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of the most characterized of several protein domains that recognize acetyl-lysine (Kac) and effect downstream function, and histone deacetylases (HDACs) that catalyze the reverse reaction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
          "text": "residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
          "text": "ther transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequenc",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
          "text": " A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural simil",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
          "text": ") are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine resi",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790315",
          "text": "Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
          "text": "tisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency. Rtt109 is a particularly interesting example ",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818759",
          "text": "enzyme A (Ac-CoA) to lysine residues of substrate peptide, thus generating CoA molecule. Later, CoA, which acts as an initiator, can embrace its aptam",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 521,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19056256",
          "text": "The ability of HATs to form distinct multi-subunit complexes provides a means to regulate HAT activity by altering substrate specificity, targeting to specific loci, enhancing acetyltransferase activity, restricting access of non-target proteins, and coordinating the multiple enzyme activities of the complex.",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 768,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27231488",
        "http://www.ncbi.nlm.nih.gov/pubmed/21908798",
        "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
        "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
        "http://www.ncbi.nlm.nih.gov/pubmed/10579936",
        "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
        "http://www.ncbi.nlm.nih.gov/pubmed/26065557",
        "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
        "http://www.ncbi.nlm.nih.gov/pubmed/25707943",
        "http://www.ncbi.nlm.nih.gov/pubmed/32764680"
      ]
    },
    {
      "id": "6432fc0457b1c7a31500001f",
      "type": "factoid",
      "body": "Which gene is most frequently mutated in hereditary angioedema ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
          "text": "he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
          "text": "), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 689,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
          "text": "used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
          "text": "The fundamental cause of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor.",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
          "text": "childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedem",
          "offsetInBeginSection": 353,
          "offsetInEndSection": 503,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
          "text": "Genetic testing revealed a heterozygous nonsense mutation of the SERPING1 gene, and a diagnosis of hereditary angioedema was made.",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
          "text": "utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
          "text": "BACKGROUND\nHereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282866",
          "text": "HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor.",
          "offsetInBeginSection": 1180,
          "offsetInEndSection": 1275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271546",
          "text": "therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. I",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 719,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30530986",
        "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/27271546",
        "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
        "http://www.ncbi.nlm.nih.gov/pubmed/8586465",
        "http://www.ncbi.nlm.nih.gov/pubmed/19477491",
        "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
        "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
        "http://www.ncbi.nlm.nih.gov/pubmed/20667118"
      ]
    },
    {
      "id": "64178edb690f196b51000025",
      "type": "summary",
      "body": "What is casimersen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "6402bf2b201352f04a000007",
      "type": "summary",
      "body": "What is the mechanism of action of tiragolumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": " (16\u00b72% [6\u00b77-25\u00b77]) in the placebo plus atezolizumab group had an objective response (p=0\u00b7031). Median progression-free survival was 5\u00b74 months (95% C",
          "offsetInBeginSection": 2161,
          "offsetInEndSection": 2311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
          "text": "tion with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically signifi",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "INTERPRETATION\nTiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.",
          "offsetInBeginSection": 2991,
          "offsetInEndSection": 3259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "BACKGROUND\nTargeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
        "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "641d8fd6690f196b51000041",
      "type": "list",
      "body": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
          "text": "This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 882,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "th a sensitivity of 73.0% and a specificity of 75.8%.\n\n\nCONCLUSIONS\nsGFAP and sNfL are likely to be good biomarkers of disease activity and disability",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468778",
          "text": "The serum levels of IL-21, IL-6, IL-17, TNF-\u03b1 and IL-10 were analyzed by ELISA assays.",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
          "text": "This article summarized the research progress in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD.",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
          "text": "toimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NM",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
          "text": "Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
          "text": "ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1384,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29478727",
          "text": "Serum immunoglobulin G autoantibodies (NMO-IgG) are identified in the majority of NMOSD patients.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
          "text": "We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers.",
          "offsetInBeginSection": 875,
          "offsetInEndSection": 987,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184342",
          "text": "CONCLUSION\nThe pattern of serum biomarkers of disease activity and disability in MOGAD showed a distinct feature from those in NMOSD with AQP4-Ab, which implicates different pathogeneses between the 2 diseases.",
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1630,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
        "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
        "http://www.ncbi.nlm.nih.gov/pubmed/34259579",
        "http://www.ncbi.nlm.nih.gov/pubmed/35401423",
        "http://www.ncbi.nlm.nih.gov/pubmed/32961928",
        "http://www.ncbi.nlm.nih.gov/pubmed/35873620",
        "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
        "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
        "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
        "http://www.ncbi.nlm.nih.gov/pubmed/29478727"
      ]
    },
    {
      "id": "6429d5c557b1c7a315000006",
      "type": "list",
      "body": "What are the major thrombotic complications in patients with COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36289613",
          "text": "n has been associated with thrombotic complications, especially venous thromboembolism. Although arterial thrombotic complications are rarely seen in ",
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
          "text": "ne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli. The endothelial expression of angiotensin-converting enzyme-2 rec",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 944,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
          "text": "These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35643053",
          "text": "Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 294,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
          "text": "Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines.",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
          "text": "INTRODUCTION\nThrombosis and bleeding are recognized complications of the novel coronavirus infection (COVID-19), with a higher incidence described particularly in the critically ill.\n\n\nMETHODS\nA retrospective review of COVID-19 patients admitted to our intensive care units (ICU) between 1 January 2020 and 31 December 2020 was performed.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
          "text": "Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34938638",
          "text": "Such complications may include the pulmonary, renal, and other organs vasculature.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32474145",
          "text": "Most of the reports on a high incidence of thrombotic complications are in relation to deep vein thrombosis and pulmonary embolism, while the evidence about arterial thrombosis in patients with COVID-19 is limited.",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 343,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33296828",
          "text": "Common thrombotic complications include pulmonary embolism, cerebral infarction, or venous thromboembolism; less commonly seen are acute myocardial injury, renal artery thrombosis, and mesenteric ischemia.",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 505,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36289613",
        "http://www.ncbi.nlm.nih.gov/pubmed/33074732",
        "http://www.ncbi.nlm.nih.gov/pubmed/34198348",
        "http://www.ncbi.nlm.nih.gov/pubmed/32474145",
        "http://www.ncbi.nlm.nih.gov/pubmed/32944087",
        "http://www.ncbi.nlm.nih.gov/pubmed/34066226",
        "http://www.ncbi.nlm.nih.gov/pubmed/35643053",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
        "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884354"
      ]
    },
    {
      "id": "6433012b57b1c7a315000022",
      "type": "summary",
      "body": "What is Cinryze?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
          "text": "ted States: Berinert(\u00ae) for treating acute attacks and Cinryze(\u00ae) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con",
          "offsetInBeginSection": 745,
          "offsetInEndSection": 895,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
          "text": "Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
          "text": "Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze\u00ae) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "o long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with ecall",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 932,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
          "text": "he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze\u2122), distributed by Lev Pharmaceuticals, was a",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 884,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "a blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "STUDY DESIGN AND METHODS\nThe analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 605,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "Additional bands in the plasma-derived products were \u03b11-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert).",
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 926,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1104,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
        "http://www.ncbi.nlm.nih.gov/pubmed/29279063",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282867",
        "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
        "http://www.ncbi.nlm.nih.gov/pubmed/33485376",
        "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
        "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
        "http://www.ncbi.nlm.nih.gov/pubmed/22282695"
      ]
    },
    {
      "id": "64179337690f196b51000034",
      "type": "yesno",
      "body": "Do machine learning-based methods outperform statistical methods for survival analysis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
          "text": " and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 718,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
          "text": "Despite their potential advantages over standard statistical methods, like their ability to model non-linear relationships and construct symbolic and interpretable models, their applications to survival analysis are at best rare, primarily because of the difficulty to appropriately handle censored data.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409119",
          "text": "on constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concor",
          "offsetInBeginSection": 1858,
          "offsetInEndSection": 2008,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
          "text": "BACKGROUND\nMachine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35316964",
          "text": "Machine learning models may outperform traditional statistical regression algorithms for predicting clinical outcomes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "CONCLUSION\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores for predicting 1-month, 3-month, and 12-month survival following liver transplantation.",
          "offsetInBeginSection": 2443,
          "offsetInEndSection": 2680,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
          "text": "g the identified various risk groups.\n\n\nRESULTS\nThe machine learning models performed very effectively in predicting the survival time: the support ve",
          "offsetInBeginSection": 1818,
          "offsetInEndSection": 1968,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "ival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model. The highest C",
          "offsetInBeginSection": 955,
          "offsetInEndSection": 1105,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33313792",
          "text": "CONCLUSIONS\nThe machine learning model's predictions were more accurate than those of the treating physician or a traditional model.",
          "offsetInBeginSection": 1614,
          "offsetInEndSection": 1746,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
        "http://www.ncbi.nlm.nih.gov/pubmed/35316964",
        "http://www.ncbi.nlm.nih.gov/pubmed/33313792",
        "http://www.ncbi.nlm.nih.gov/pubmed/20153956",
        "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
        "http://www.ncbi.nlm.nih.gov/pubmed/35571512",
        "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
        "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
        "http://www.ncbi.nlm.nih.gov/pubmed/34161901"
      ]
    },
    {
      "id": "63f03c47f36125a42600001e",
      "type": "factoid",
      "body": "ZF2001 is used for which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35034583",
          "text": "e (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibod",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 820,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
          "text": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
          "text": " CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
          "text": "iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
          "text": "es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 748,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
          "text": "Background\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311493",
          "text": "ZF2001 has been approved for emergency use in China, Uzbekistan, Indonesia, and Columbia.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1048,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
          "text": "eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased",
          "offsetInBeginSection": 2528,
          "offsetInEndSection": 2678,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
        "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
        "http://www.ncbi.nlm.nih.gov/pubmed/35034583",
        "http://www.ncbi.nlm.nih.gov/pubmed/35311493",
        "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
        "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
        "http://www.ncbi.nlm.nih.gov/pubmed/36426361"
      ]
    },
    {
      "id": "642c82c557b1c7a315000012",
      "type": "factoid",
      "body": "What mammal has the lowest known chromosome number?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
          "text": "The species have 2n=36, a number considered as a pleisomorphic feature in Arecoideae since the modern species, according to floral morphology, have the lowest chromosome number (2n=28 and 2n=30).",
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1282,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
          "text": "kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "This system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\u00a0=\u00a03).",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
          "text": "Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 848,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
          "text": " patchy distribution, poor records and low abundances. It is also the phyllotine with the lowest known diploid chromosome number (2n = 18), however it",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
          "text": "The referred species presented the lowest chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region.",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5444269",
          "text": "The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
          "text": "o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 295,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
          "text": "The chocolate gourami, Sphaerichthys osphromonoides, has the lowest chromosome number reported for fishes, with 2n = 16 and n = 8.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9691174",
          "text": "osso, Central Brazil, represents the lowest chromosome number known for rodents. One female with nine chromosomes due to sex chromosome monosomy (2n =",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 290,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
        "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
        "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
        "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
        "http://www.ncbi.nlm.nih.gov/pubmed/9691174",
        "http://www.ncbi.nlm.nih.gov/pubmed/17189914",
        "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
        "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
        "http://www.ncbi.nlm.nih.gov/pubmed/33089966"
      ]
    },
    {
      "id": "6429b41757b1c7a315000004",
      "type": "list",
      "body": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "text": "n structure and function by modifying the biochemical properties of key amino acids. Histone methylation events, especially on arginine- and lysine-re",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 479,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22122749"
      ]
    },
    {
      "id": "643305b257b1c7a315000025",
      "type": "factoid",
      "body": "Which company produces Ruconest?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 619,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
          "text": "This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(\u00ae) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.",
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1043,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
          "text": "Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
        "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
        "http://www.ncbi.nlm.nih.gov/pubmed/26106828"
      ]
    },
    {
      "id": "641635fa690f196b5100001c",
      "type": "factoid",
      "body": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977513",
          "text": "Diagnosis usually occurs in childhood and is confirmed through genetic testing and/or muscle biopsy.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
          "text": "The average age at diagnosis is 4.83 years but an early diagnosis is possible.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638505",
          "text": "ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 387,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "RESULTS\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "METHODS\nOnline surveys were sent to three groups: (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (\u226514 years), (b) parents and guardians and (c) neuromuscular clinicians in the UK NorthStar Clinical Network.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
          "text": "A well examined muscular biopsy is usually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate.",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026234",
          "text": "ion caused by Duchenne muscular dystrophy are usually detected during adolescence. However, decreased physical activity can allow better tolerance of ",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
          "text": "n age of 3 years, but the accurate diagnosis was made at a mean age of 5.7 years. In only 15% of children, the disease was diagnosed in the first four",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 552,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
        "http://www.ncbi.nlm.nih.gov/pubmed/1667037",
        "http://www.ncbi.nlm.nih.gov/pubmed/2476078",
        "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
        "http://www.ncbi.nlm.nih.gov/pubmed/19394035",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
        "http://www.ncbi.nlm.nih.gov/pubmed/16638505",
        "http://www.ncbi.nlm.nih.gov/pubmed/10436681",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180"
      ]
    },
    {
      "id": "6402c868201352f04a00000b",
      "type": "yesno",
      "body": "Was erythropoietin effective for optic neuritis in the TONE trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
          "text": "CONCLUSION\nErythropoietin may be effective, but should be used with caution.",
          "offsetInBeginSection": 1438,
          "offsetInEndSection": 1514,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "INTERPRETATION\nThese results give the first indications that erythropoietin might be neuroprotective in optic neuritis.",
          "offsetInBeginSection": 1767,
          "offsetInEndSection": 1886,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
          "text": "Few data are available concerning the effect of ivermectin on active optic neuritis.",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 602,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9103884",
          "text": "ned pathology, therapy of this disease, and summarized our previous cases. Intravenous methylpredonisolone treatment is effective from our experience.",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
          "text": "icosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "ys or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started ",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1697,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
          "text": "oup than in the control (P<.05).\n\n\nCONCLUSIONS\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in ",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
          "text": "OBJECTIVE\nTo investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "OBJECTIVE\nBased on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
          "text": "Functional and histo pathological data of retinal ganglion cells and optic nerves revealed that neuron and axon protection was most effective when erythropoietin treatment that was started at immunization was combined with high-dose methylprednisolone therapy given from days 1 to 3 of MOG-induced experimental autoimmune encephalomyelitis.",
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1487,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7749521",
        "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
        "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
        "http://www.ncbi.nlm.nih.gov/pubmed/27706045",
        "http://www.ncbi.nlm.nih.gov/pubmed/15601662",
        "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
        "http://www.ncbi.nlm.nih.gov/pubmed/9103884",
        "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
        "http://www.ncbi.nlm.nih.gov/pubmed/7821473",
        "http://www.ncbi.nlm.nih.gov/pubmed/26932144"
      ]
    },
    {
      "id": "6424154d690f196b5100004a",
      "type": "summary",
      "body": "What is the R value with respect to hepatoxicity",
      "snippets": [],
      "documents": []
    },
    {
      "id": "64299b6a57b1c7a315000001",
      "type": "yesno",
      "body": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
          "text": "BACKGROUND\nIn the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
          "text": "Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2.",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "ly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiven",
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1464,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
          "text": "ively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization co",
          "offsetInBeginSection": 1963,
          "offsetInEndSection": 2113,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
          "text": "Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.",
          "offsetInBeginSection": 372,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35025038",
          "text": "spreads rapidly with an average doubling time of two days. The disease so far has been mild as compared with delta. Though previous infection and vacc",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 595,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
          "text": "aled multiple cystic cavitations.\n\n\nCONCLUSION\nAlthough COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-associat",
          "offsetInBeginSection": 1182,
          "offsetInEndSection": 1332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35835638",
        "http://www.ncbi.nlm.nih.gov/pubmed/35025038",
        "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
        "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
        "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
        "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
        "http://www.ncbi.nlm.nih.gov/pubmed/36090988"
      ]
    },
    {
      "id": "6432ffdf57b1c7a315000021",
      "type": "summary",
      "body": "What is hereditary angioedema?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
          "text": "In addition to edema of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 718,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
          "text": "The disease can either present with hypocomplementemia owing to the presence of pathogenic variants in the gene encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevated estrogen levels owing to gain-of-function variants in the genes encoding coagulation proteins involved in the kallikrein-kinin system (namely, coagulation FXII [FXII-associated hereditary angioedema], plasminogen [PLG-associated hereditary angioedema], and high-molecular-weight kininogen [KNG1-associated hereditary angioedema]).",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 1195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
          "text": "Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1-esterase inhibitor of the classic complement pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31283393",
          "text": "Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
          "text": "Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
          "text": "Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865240",
          "text": "Hereditary angioedema is a rare disease, which is caused by deficiency of compleman c1 esterase inhibitor regulatory protein in the compleman system.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2371584",
          "text": "Hereditary angioedema is a rare autosomal dominant disorder due to the deficiency of functionally active C1-inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18329867",
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/21251443",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880254",
        "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
        "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
        "http://www.ncbi.nlm.nih.gov/pubmed/12572187",
        "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
        "http://www.ncbi.nlm.nih.gov/pubmed/8506211",
        "http://www.ncbi.nlm.nih.gov/pubmed/25511656"
      ]
    },
    {
      "id": "64178ec2690f196b51000024",
      "type": "summary",
      "body": "What is viltolarsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "64040bd8201352f04a00000e",
      "type": "yesno",
      "body": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6422e7f0690f196b51000045",
      "type": "list",
      "body": "Hepcidin is a key regulator of what processes?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
          "text": "Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
          "text": "Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293278",
          "text": "Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25782630",
          "text": "Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
          "text": "Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852110",
          "text": "Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30530987",
          "text": "Hepcidin is the master regulator of iron metabolism. It plays a key role in the regulation of iron transport across the duodenal epithelium, which in ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24123375",
          "text": "The expression of hepcidin is significantly induced by iron overload, inflammation, and infection of pathogens.",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33820875",
          "text": "ved in postmenopausal osteoporosis. Hepcidin is a key regulator of iron homeostasis. However, the exact role of hepcidin in bone metabolism and the un",
          "offsetInBeginSection": 223,
          "offsetInEndSection": 373,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356737",
          "text": "central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21439478",
        "http://www.ncbi.nlm.nih.gov/pubmed/33820875",
        "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852110",
        "http://www.ncbi.nlm.nih.gov/pubmed/34755647",
        "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
        "http://www.ncbi.nlm.nih.gov/pubmed/18936232",
        "http://www.ncbi.nlm.nih.gov/pubmed/30374287",
        "http://www.ncbi.nlm.nih.gov/pubmed/30469435",
        "http://www.ncbi.nlm.nih.gov/pubmed/17768112"
      ]
    },
    {
      "id": "6429ee7457b1c7a31500000b",
      "type": "yesno",
      "body": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
          "text": "The COVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such occurrences.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 311,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
          "text": "tients with BECTS reported having side effects; all effects were mild that could be relieved themselves. For Sinopharm (Beijing): BBIBP-CorV (Vero cel",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1010,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
          "text": "The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%).",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
          "text": "etween 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.\n\n\nConclusions\nAccording t",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1664,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
          "text": "cination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater",
          "offsetInBeginSection": 2211,
          "offsetInEndSection": 2361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
          "text": "The common side effects reported following Covid-19 vaccination were mostly self-restricted local reactions that resolved quickly.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767100",
          "text": "The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX).",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 921,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
          "text": "d individuals with DS (median age = 19.5\u00a0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1093,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
          "text": "period of 3-13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent d",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 859,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
          "text": "Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34767100",
        "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
        "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
        "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
        "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
        "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236842",
        "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
        "http://www.ncbi.nlm.nih.gov/pubmed/35775049"
      ]
    },
    {
      "id": "6433050157b1c7a315000024",
      "type": "factoid",
      "body": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
          "text": "BACKGROUND\nConestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
          "text": "BACKGROUND\nRecombinant human C1-inhibitor (rhC1INH; Ruconest\u00ae) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
          "text": " an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 369,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21753889",
          "text": "n findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement product",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 358,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, ",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
          "text": " likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 546,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
        "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
        "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
        "http://www.ncbi.nlm.nih.gov/pubmed/21753889"
      ]
    },
    {
      "id": "6417900b690f196b5100002a",
      "type": "factoid",
      "body": "What type of DMD can viltolarsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
          "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
          "text": "nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
          "text": "n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 570,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
          "text": "OBJECTIVE\nTo optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
        "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
        "http://www.ncbi.nlm.nih.gov/pubmed/29060790",
        "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
        "http://www.ncbi.nlm.nih.gov/pubmed/34092651",
        "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
        "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/26037351"
      ]
    },
    {
      "id": "63f57ea133942b094c000005",
      "type": "list",
      "body": "What is the triad of the Cat eye syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
          "text": "The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
          "text": "osome 22q11. The patients demonstrate specific abnormalities of heart, kidney, and eye. Here we attempted to produce a model for this defect by expres",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
          "text": "The cat eye syndrome, blepharophimosis or Kohn-Romano syndrome, Rieger syndrome, and other disorders are discussed in relationship to this entity.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
          "text": "riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/410302",
          "text": "hniques, we studied a child with typical cat-eye syndrome and ocular retraction syndrome. Although the mother was was chromosomally normal, other mate",
          "offsetInBeginSection": 38,
          "offsetInEndSection": 188,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911297",
          "text": "The classic clinical triad includes coloboma of the iris, ears, and anal malformations.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
          "text": "In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
          "text": "e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
        "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
        "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
        "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
        "http://www.ncbi.nlm.nih.gov/pubmed/410302",
        "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
        "http://www.ncbi.nlm.nih.gov/pubmed/35911297"
      ]
    },
    {
      "id": "64281a47690f196b5100004f",
      "type": "yesno",
      "body": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
          "text": "1), with doses and intervals according to body weight. Little is known as to its use in infants; the aim of this study was to describe treatment outco",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 277,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients.",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1673,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
          "text": "ney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxalate prod",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
        "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
        "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
        "http://www.ncbi.nlm.nih.gov/pubmed/33985991"
      ]
    },
    {
      "id": "6429cfb557b1c7a315000005",
      "type": "yesno",
      "body": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
          "text": "Asthma should be managed as outlined in local and international guidelines.Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34476396"
      ]
    },
    {
      "id": "6432f75757b1c7a31500001d",
      "type": "yesno",
      "body": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved potential for combination with other targeted therapies.",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 995,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
          "text": "TKi-related adverse events, but major rates of neutropenia, and its approval is awaited. With the aim of overcoming drug resistance, noncovalent BTKi ",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 826,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32731259",
          "text": ", a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease w",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 348,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have",
          "offsetInBeginSection": 3152,
          "offsetInEndSection": 3302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 661,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
          "text": "Whether zanubrutinib, a second-generation selective BTK inhibitor, has similar effects as ibrutinib remains to be determined.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
          "text": "Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
          "text": " for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patien",
          "offsetInBeginSection": 118,
          "offsetInEndSection": 268,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31933167",
        "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
        "http://www.ncbi.nlm.nih.gov/pubmed/32731259",
        "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/34858810"
      ]
    },
    {
      "id": "64178fea690f196b51000028",
      "type": "factoid",
      "body": "What types of DMD can eteplirsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
          "text": "OBJECTIVE\nIn prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
          "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
          "text": "BACKGROUND\nExon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "text": "Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 346,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
          "text": "ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035327",
          "text": "he first AO-based drug, eteplirsen (Exondys 51), developed for DMD exon 51 skipping. An accurate and reproducible method to quantify exon skipping eff",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA.",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 482,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217",
          "text": "holino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27936976",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
        "http://www.ncbi.nlm.nih.gov/pubmed/29771942",
        "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
        "http://www.ncbi.nlm.nih.gov/pubmed/29035327",
        "http://www.ncbi.nlm.nih.gov/pubmed/29301272",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171538",
        "http://www.ncbi.nlm.nih.gov/pubmed/33610829",
        "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171554"
      ]
    },
    {
      "id": "63eef94ff36125a426000010",
      "type": "yesno",
      "body": "Is Cinpanemab effective for Parkinson\u2019s Disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "The trial was stopped after the week 72 interim analysis owing to lack of efficacy.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
          "text": "Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID).",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "Cinpanemab, a human-derived monoclonal antibody that binds to \u03b1-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
          "text": "in patients with Parkinson\u2019s disease (PD). However, its therapeutic mechanism of action is unknown. The healthy striatum exhibits rich dynamics result",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 267,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
          "text": "The present therapeutic drugs for PD can only alleviate the patients\u2019 symptoms, but cannot prevent or delay progression of the disease.",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
          "text": "Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect.",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
          "text": "Conclusion\nAs detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
          "text": " associated with neurodegeneration  but  have  failed  to  identify  preventive  or  curative  therapies.  This  failure  mainly  originates  from  th",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 383,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
        "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
        "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
        "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
        "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
        "http://www.ncbi.nlm.nih.gov/pubmed/35921450"
      ]
    },
    {
      "id": "6426d131690f196b5100004e",
      "type": "factoid",
      "body": "In what organ would you find the Ashwell receptor?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
          "text": "The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
          "text": "This review will focus on the mechanisms of platelet senescence with specific emphasis on the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
        "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
        "http://www.ncbi.nlm.nih.gov/pubmed/18488037"
      ]
    },
    {
      "id": "6429e17657b1c7a315000007",
      "type": "list",
      "body": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
          "text": "The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957309",
          "text": "We tested 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of active enhancers.",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
          "text": "These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
          "text": "stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements ",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 817,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526891",
          "text": "We show that RFECS not only leads to more accurate and precise prediction of enhancers than previous methods, but also helps identify the most informative and robust set of three chromatin marks for enhancer prediction.",
          "offsetInBeginSection": 1030,
          "offsetInEndSection": 1249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
          "text": "Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 776,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22328731",
          "text": "The combined results indicate that ChromaGenSVM comfortably outperforms previously published methods and that enhancers are best predicted by specific combinations of histone methylation and acetylation marks.",
          "offsetInBeginSection": 1225,
          "offsetInEndSection": 1434,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22491032",
          "text": " of specific transcription factors to enhancers and existing histone modifications. In this review, we present insights into the mechanisms of enhance",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
          "text": "Furthermore, we observed possible feedbacks to control chromatin dynamics as the found motifs appear in the promoters or enhancers associated with various histone modification enzymes.",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1490,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29754476",
          "text": "on of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the c",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 575,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21847099",
        "http://www.ncbi.nlm.nih.gov/pubmed/23473601",
        "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
        "http://www.ncbi.nlm.nih.gov/pubmed/28916725",
        "http://www.ncbi.nlm.nih.gov/pubmed/22491032",
        "http://www.ncbi.nlm.nih.gov/pubmed/23526891",
        "http://www.ncbi.nlm.nih.gov/pubmed/24885402",
        "http://www.ncbi.nlm.nih.gov/pubmed/30755522",
        "http://www.ncbi.nlm.nih.gov/pubmed/22328731",
        "http://www.ncbi.nlm.nih.gov/pubmed/35801925"
      ]
    },
    {
      "id": "643306cc57b1c7a315000027",
      "type": "yesno",
      "body": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
          "text": "These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to detect all types of pathogens.",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
          "text": "h attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules. Bacterial allosteric transcription factors (",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
          "text": "This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.",
          "offsetInBeginSection": 1361,
          "offsetInEndSection": 1562,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
          "text": "ns-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection. Herein, we introduce a new type of Cas12a reporter, G-triplex ",
          "offsetInBeginSection": 24,
          "offsetInEndSection": 174,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
        "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
        "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
        "http://www.ncbi.nlm.nih.gov/pubmed/33991961"
      ]
    },
    {
      "id": "64178ffb690f196b51000029",
      "type": "factoid",
      "body": "What type of DMD can casimersen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
          "text": "Casimersen (Amondys 45\u2122) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\u00a045 skipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1032,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
          "text": "disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
          "text": "Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1628,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
          "text": "sed as potential treatments for inherited myopathies, such as Duchenne muscular dystrophy (DMD). The success of myoblast implantation in mouse models,",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
        "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
        "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
        "http://www.ncbi.nlm.nih.gov/pubmed/25982038",
        "http://www.ncbi.nlm.nih.gov/pubmed/25669899",
        "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
        "http://www.ncbi.nlm.nih.gov/pubmed/25365558"
      ]
    },
    {
      "id": "63eeefc5f36125a426000009",
      "type": "factoid",
      "body": "What is targeted by CIS43LS?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
          "text": " dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have implications for the seasonal control of mala",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1250,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34511592"
      ]
    },
    {
      "id": "6415b422690f196b5100000a",
      "type": "summary",
      "body": "What does Cal-light do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 292,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
      ]
    },
    {
      "id": "64172bb2690f196b5100001e",
      "type": "factoid",
      "body": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
          "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
          "text": "The RNA polymerase from bacteriophage T4-infected Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits and by binding several virus-encoded subunits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
          "text": "Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
          "text": "from a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces t",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 789,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
          "text": "A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
          "text": "kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": " facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1767,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16798040",
          "text": "During transcription initiation by bacterial RNA polymerase, the sigma subunit recognizes the -35 and -10 promoter elements; free sigma, however, does not bind DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": "RNA polymerase did bind to the promoter once the methylated Ada protein had bound to the upstream sequence.",
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1087,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27558998",
          "text": "In a canonical \u03c3 factor, region 2.3 amino acids bind non-template strand DNA, trapping the promoter in a single-stranded state required for initiation of transcription.",
          "offsetInBeginSection": 834,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7556074",
        "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
        "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
        "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
        "http://www.ncbi.nlm.nih.gov/pubmed/16798040",
        "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
        "http://www.ncbi.nlm.nih.gov/pubmed/27558998",
        "http://www.ncbi.nlm.nih.gov/pubmed/3465670",
        "http://www.ncbi.nlm.nih.gov/pubmed/10593606",
        "http://www.ncbi.nlm.nih.gov/pubmed/6263495"
      ]
    },
    {
      "id": "63f9ccdc33942b094c00000f",
      "type": "yesno",
      "body": "Is PRP-40 involved in microexon splicing?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "ion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dep",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 677,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34348142"
      ]
    },
    {
      "id": "641790d6690f196b5100002d",
      "type": "factoid",
      "body": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
          "text": "nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 772,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625891",
          "text": "wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 273,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
          "text": "Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25643053",
          "text": "ents with Duchenne muscular dystrophy aged 17.1 \u00b1 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 \u00b1 1",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 791,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
          "text": "Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s.",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3198893",
          "text": "ot orthoses at the point of loss of ambulation, between the ages of 6 and 12 years. There was an inverse relationship between the severity of the scol",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3632394",
          "text": "f Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate. Survival curve analysis an",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 237,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
          "text": "trophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advance",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 243,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322188",
          "text": "ked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or ca",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3632394",
        "http://www.ncbi.nlm.nih.gov/pubmed/31922454",
        "http://www.ncbi.nlm.nih.gov/pubmed/17257866",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/27382620",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
        "http://www.ncbi.nlm.nih.gov/pubmed/33215271",
        "http://www.ncbi.nlm.nih.gov/pubmed/29067658",
        "http://www.ncbi.nlm.nih.gov/pubmed/25643053"
      ]
    },
    {
      "id": "6404199d201352f04a000019",
      "type": "yesno",
      "body": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "Conclusions: Our real-world study supports the tolerability, safety, and effectiveness of ocrelizumab in clinical practice.",
          "offsetInBeginSection": 1453,
          "offsetInEndSection": 1576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
          "text": " remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and even",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ",
          "offsetInBeginSection": 1249,
          "offsetInEndSection": 1399,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
          "text": "OBJECTIVES\nOcrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
          "text": "BACKGROUND\nOcrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32607256",
          "text": "CONCLUSION\nOcrelizumab can stabilize disability progression in patients with PPMS.",
          "offsetInBeginSection": 1108,
          "offsetInEndSection": 1190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
          "text": "lizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) ",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30677733",
          "text": "rve (SUCRA) values.\n\n\nRESULTS\nResults suggest that ocrelizumab has superior efficacy to 10 of the 17 treatments in the 12-week confirmed disability pr",
          "offsetInBeginSection": 1412,
          "offsetInEndSection": 1562,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30008443",
          "text": "Here, we review the evidence for the safety and effectiveness of ocrelizumab.",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33352355",
          "text": "ng therapy (DMT) for primary progressive multiple sclerosis (MS). Although effective, adverse infusion-related reactions (IRR), such as erythema, prur",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35079395",
        "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33948072",
        "http://www.ncbi.nlm.nih.gov/pubmed/30677733",
        "http://www.ncbi.nlm.nih.gov/pubmed/33352355",
        "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964555",
        "http://www.ncbi.nlm.nih.gov/pubmed/33356643",
        "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
        "http://www.ncbi.nlm.nih.gov/pubmed/32607256"
      ]
    },
    {
      "id": "641b7bba690f196b5100003e",
      "type": "summary",
      "body": "How is Indocyanine green (ICG) used?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
          "text": "s an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
          "text": "We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
          "text": "Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
          "text": "Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12963458",
          "text": "We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable.",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35662771",
          "text": "Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12880353",
          "text": "Its complex spectral behavior and low quantum yield limits some applications.",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31129192",
          "text": "Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871512",
          "text": "OBJECT\nRecently, intraoperative fluorescence angiography in which indocyanine green (ICG) is used as a tracer has been introduced as a novel technique to confirm successful aneurysm clipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19065196",
          "text": "Indocyanine green (ICG) is a fluorescent probe used in clinical imaging. However, its utility remains limited by optical instability, rapid circulatio",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
        "http://www.ncbi.nlm.nih.gov/pubmed/34589458",
        "http://www.ncbi.nlm.nih.gov/pubmed/36055879",
        "http://www.ncbi.nlm.nih.gov/pubmed/12880353",
        "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
        "http://www.ncbi.nlm.nih.gov/pubmed/10946079",
        "http://www.ncbi.nlm.nih.gov/pubmed/19790157",
        "http://www.ncbi.nlm.nih.gov/pubmed/23727789",
        "http://www.ncbi.nlm.nih.gov/pubmed/27051499",
        "http://www.ncbi.nlm.nih.gov/pubmed/32021082"
      ]
    },
    {
      "id": "6428da74690f196b51000052",
      "type": "factoid",
      "body": "What is the process that generates multiple transcripts from the same gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
          "text": "Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852095",
          "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
          "text": "ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
          "text": "nt accordingly by regulating gene expression at multiple levels. Alternative splicing (AS), a widespread mechanism in eukaryotes that post-transcripti",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
          "text": "Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28942592",
          "text": "Alternative polyadenylation is an important and pervasive mechanism that generates heterogeneous 3'-termini of mRNA and is considered an important regulator of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35821097",
          "text": "at give rise to phenotypic diversity in multicellular organisms. Alternative splicing generates multiple transcripts from a single gene, enriching the",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064309",
          "text": "Alternative splicing of pre-mRNA is one of the main mechanisms regulating gene expression that generates multiple transcripts from one gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18817741",
        "http://www.ncbi.nlm.nih.gov/pubmed/24130571",
        "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
        "http://www.ncbi.nlm.nih.gov/pubmed/11868989",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569514",
        "http://www.ncbi.nlm.nih.gov/pubmed/11274164",
        "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
        "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
        "http://www.ncbi.nlm.nih.gov/pubmed/28942592",
        "http://www.ncbi.nlm.nih.gov/pubmed/29074233"
      ]
    },
    {
      "id": "63f9cdcc33942b094c000013",
      "type": "yesno",
      "body": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "64179aac690f196b51000037",
      "type": "factoid",
      "body": "What is the life expectancy for Duchenne muscular dystrophy patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
          "text": "eater Los Angeles area. Regardless of their ages, which ranged from 12 years to 21, the majority of the patients, as well as the majority of the paren",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
          "text": "A total of 85 boys with Duchenne muscular dystrophy aged 8-18 years and 136 age, sex and living place matched healthy controls were included in this study.",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 314,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
          "text": "tients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effect",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
          "text": "lar dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines rega",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
          "text": "and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g",
          "offsetInBeginSection": 45,
          "offsetInEndSection": 195,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
          "text": "RESULTS\nThe mean (SD) age was 26 (6) years and the mean age at which mechanical ventilation had initiated in the patients was 21 (5) years.",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 568,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34645707",
          "text": "Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4).",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1085,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500",
          "text": "trophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy expe",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 300,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
          "text": "f the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years. Various new drug trials for muscular dystroph",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34645707",
        "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
        "http://www.ncbi.nlm.nih.gov/pubmed/1450492",
        "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275245",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482750",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
        "http://www.ncbi.nlm.nih.gov/pubmed/3694224",
        "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
        "http://www.ncbi.nlm.nih.gov/pubmed/33075081"
      ]
    },
    {
      "id": "64041e97201352f04a00001e",
      "type": "yesno",
      "body": "Is daridorexant effective for insomnia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
          "text": "BACKGROUND\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": "were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\u2009=\u20091.19; 95% ",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1011,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "OBJECTIVE\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
          "text": "in the two placebo-controlled phase III trials that evaluated the efficacy and safety of daridorexant. The DCE design was informed by a two-phase qual",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 429,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
          "text": "e events were nasopharyngitis and headache.\n\n\nCONCLUSION\nDaridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1086,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": " p=0\u00b7012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for",
          "offsetInBeginSection": 4108,
          "offsetInEndSection": 4258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": "th 1; -1\u00b70 [-2\u00b70 to 0\u00b701], p=0\u00b7053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared",
          "offsetInBeginSection": 3306,
          "offsetInEndSection": 3456,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": " (RR\u2009=\u20092.01; 95% CI, 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly h",
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1266,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
          "text": "Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.",
          "offsetInBeginSection": 1528,
          "offsetInEndSection": 1629,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
          "text": "In this randomized, double-blind, placebo-controlled, two-period crossover study, the effect of the dual orexin receptor antagonist daridorexant was evaluated on nighttime respiratory function and sleep in 28 patients with mild and moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
        "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
        "http://www.ncbi.nlm.nih.gov/pubmed/32937014",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
        "http://www.ncbi.nlm.nih.gov/pubmed/33305817",
        "http://www.ncbi.nlm.nih.gov/pubmed/32603512",
        "http://www.ncbi.nlm.nih.gov/pubmed/32778207",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
        "http://www.ncbi.nlm.nih.gov/pubmed/35065036"
      ]
    },
    {
      "id": "6422ee03690f196b51000046",
      "type": "factoid",
      "body": "What cells produce erythroferrone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
          "text": "Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1012,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30097509",
          "text": "Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
          "text": "Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
          "text": "Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
          "text": "pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 455,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
          "text": "Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.",
          "offsetInBeginSection": 1033,
          "offsetInEndSection": 1239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
          "text": "Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.",
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31846624",
          "text": " blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
          "text": "Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 621,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494918",
          "text": "In this issue of Blood, Kautz et al show that the ablation of the erythroid-derived factor erythroferrone (ERFE), which has been shown to be highly expressed in \u03b2-thalassemic mice, restores hepcidin levels and corrects iron overload.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
        "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
        "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
        "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
        "http://www.ncbi.nlm.nih.gov/pubmed/28438754",
        "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
        "http://www.ncbi.nlm.nih.gov/pubmed/26494918",
        "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
        "http://www.ncbi.nlm.nih.gov/pubmed/34827208"
      ]
    },
    {
      "id": "6429f86657b1c7a31500000d",
      "type": "summary",
      "body": "What is the role of the Mediator in gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
          "text": "Therefore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for C. elegans development.",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 948,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
          "text": "The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
        "http://www.ncbi.nlm.nih.gov/pubmed/21854862"
      ]
    },
    {
      "id": "6415c0df690f196b51000010",
      "type": "factoid",
      "body": "What does FBDD stand for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
          "text": "Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
          "text": "Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
          "text": "Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
          "text": "Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32133344",
          "text": "Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
          "text": "Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
          "text": "Fragment-Based Drug Discovery (FBDD) has been recognized as a newly emerging lead discovery methodology that involves biophysical fragment screening and chemistry-driven fragment-to-lead stages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32592867",
          "text": "Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the academic and industrial context, to enhance hit identification for previously considered undruggable biological targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32133344",
        "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
        "http://www.ncbi.nlm.nih.gov/pubmed/20190516",
        "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
        "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
        "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
        "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
        "http://www.ncbi.nlm.nih.gov/pubmed/32592867"
      ]
    },
    {
      "id": "64041dae201352f04a00001d",
      "type": "yesno",
      "body": "Is deucravacitinib effective for psoriasis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
          "text": "The latest IL-17 and IL-23 inhibitors include bimekizumab, netakimab and mirikizumab as well as oral small molecules, such as deucravacitinib, a tyrosine kinase 2 selective inhibitor, and piclidenoson, an agonist of the Gi protein-associated A3 adenosine receptor.",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": " oral psoriasis treatments are needed.\n\n\nOBJECTIVE\nTo compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibit",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "so reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromb",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1265,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
          "text": "Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast.",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 710,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
          "text": "OBJECTIVE\nTo evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
          "text": "of deucravacitinib versus lower doses or placebo.\n\n\nCONCLUSION\nRobust clinical efficacy with deucravacitinib treatment was associated with decreases i",
          "offsetInBeginSection": 1563,
          "offsetInEndSection": 1713,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "CONCLUSION\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event ",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 1052,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
          "text": "s the closely related Janus kinases (JAKs) 1/2/3. Deucravacitinib was efficacious in phase 2 and 3 psoriasis trials, without clinical or laboratory pa",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 436,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
        "http://www.ncbi.nlm.nih.gov/pubmed/34471993",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
        "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
        "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
        "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
        "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747941"
      ]
    },
    {
      "id": "6415b6eb690f196b5100000b",
      "type": "list",
      "body": "What processes do orexin/hypocretin neurons regulate?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
          "text": "However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
          "text": " have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
          "text": "This peptide is believed to be involved in regulating feeding and wakefulness.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 342,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
          "text": "is a critical regulator of physiological processes including sleep/wakefulness and feeding. Using organotypic slice culture of rat hypothalamus, we fo",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10624957",
          "text": "Orexin (hypocretin) appears to play a role in the regulation of energy balances.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12495630",
          "text": "Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
          "text": "hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32135427",
          "text": " to orchestrate diverse functions including sleep, reward processing, food intake, thermogenesis, and mood. Since the hypocretins/orexins were discove",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 247,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20861370",
          "text": "Orexin neurons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025809",
          "text": "ntral nervous system to control sleep and arousal, circadian rhythms, metabolism, reward pathways, and other behaviors. Dysfunction of orexin/hypocret",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 448,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20861370",
        "http://www.ncbi.nlm.nih.gov/pubmed/36457878",
        "http://www.ncbi.nlm.nih.gov/pubmed/26724374",
        "http://www.ncbi.nlm.nih.gov/pubmed/11532254",
        "http://www.ncbi.nlm.nih.gov/pubmed/10624957",
        "http://www.ncbi.nlm.nih.gov/pubmed/26322330",
        "http://www.ncbi.nlm.nih.gov/pubmed/15848807",
        "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
        "http://www.ncbi.nlm.nih.gov/pubmed/12946712",
        "http://www.ncbi.nlm.nih.gov/pubmed/22813966"
      ]
    },
    {
      "id": "6428da47690f196b51000051",
      "type": "yesno",
      "body": "Can the epigenetic status of introns affect gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
          "text": "However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213601",
          "text": "Epigenetic modifications affect gene expression and thereby govern a wide range of biological processes such as differentiation, development and tumorigenesis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
          "text": "n, and their contributions to genetic diversity and evolution, remain poorly understood. In this study, we investigated the genome-wide distribution o",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 519,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
          "text": "and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression. The nucleosome formation potential is al",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 216,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
          "text": "Introns can increase gene expression levels using a variety of mechanisms collectively referred to as Intron Mediated Enhancement (IME).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
          "text": "Introns exist in the transcribed DNA and the nascent RNA, and could affect expression from either location.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
          "text": "Epigenetic modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
          "text": "However, in yeast only 283 of the 6000 genes contain introns and their impact on cell function is not clear.",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593031",
          "text": "Epigenetic variation, such as heritable changes of DNA methylation, can affect gene expression and thus phenotypes, but examples of natural epimutations are few and little is known about their stability and frequency in nature.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010918",
          "text": "uch the same way as intergenic TEs, they are targeted by repressive epigenetic marks for transcriptional silencing. Silenced intragenic TEs generally ",
          "offsetInBeginSection": 217,
          "offsetInEndSection": 367,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
        "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
        "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
        "http://www.ncbi.nlm.nih.gov/pubmed/30010918",
        "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
        "http://www.ncbi.nlm.nih.gov/pubmed/23593031",
        "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
        "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
        "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
        "http://www.ncbi.nlm.nih.gov/pubmed/24213601"
      ]
    },
    {
      "id": "6415c5d4690f196b51000014",
      "type": "list",
      "body": "What was Keytruda originally approved for by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
          "text": "ons in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-ce",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 468,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
          "text": " Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 368,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
          "text": "rug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in s",
          "offsetInBeginSection": 1937,
          "offsetInEndSection": 2087,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
          "text": "Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
          "text": "Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates.",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 1133,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
        "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
        "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
        "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
        "http://www.ncbi.nlm.nih.gov/pubmed/34156377"
      ]
    },
    {
      "id": "63f5713733942b094c000003",
      "type": "summary",
      "body": "What are clinical features of the Achard-Thiers syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
          "text": "The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/518037",
          "text": "The clinical and neuroradiological features in 4 patients with the syndrome of aberrant regeneration of the third nerve are presented.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/518037",
        "http://www.ncbi.nlm.nih.gov/pubmed/1201353"
      ]
    },
    {
      "id": "642d4c9b57b1c7a315000013",
      "type": "yesno",
      "body": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6429fe4e57b1c7a31500000f",
      "type": "summary",
      "body": "What are coactivators?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
          "text": "ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1029,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843848",
          "text": "Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
          "text": "Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
          "text": "development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": "ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans",
          "offsetInBeginSection": 413,
          "offsetInEndSection": 563,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
          "text": "Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
          "text": "relevant brain regions coexpress nuclear receptor coactivators and steroid receptors. Confocal analysis revealed that in oestrogen-primed rats, most o",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16604175",
          "text": "Estrogen receptors are hormone-inducible transcription factors requiring coactivators such as members of the SRC/p160 family to modulate the transcription of their target genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances transcriptional activation by the estrogen receptor and other nuclear receptors.",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 638,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15814849",
        "http://www.ncbi.nlm.nih.gov/pubmed/14766010",
        "http://www.ncbi.nlm.nih.gov/pubmed/28607951",
        "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
        "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
        "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
        "http://www.ncbi.nlm.nih.gov/pubmed/11108858",
        "http://www.ncbi.nlm.nih.gov/pubmed/15016838",
        "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
        "http://www.ncbi.nlm.nih.gov/pubmed/17046230"
      ]
    },
    {
      "id": "6412331b201352f04a000038",
      "type": "factoid",
      "body": "What are PROTACs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
          "text": "Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
          "text": "Proteolysis-targeting chimeras (PROTACs), bifunctional molecules consisting of a ligand of protein of interest (POI), an E3 ligase ligand and a linker, have been developed to hijack the ubiquitin-proteasome system (UPS) to induce different POIs degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35001407",
          "text": "Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
          "text": "Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs) is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relatively high molecular weight.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
          "text": "h the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a li",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
          "text": "ive technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of inter",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35702041",
          "text": "Proteolysis-targeting chimaeras (PROTACs) have been developed to be an emerging technology for targeted protein degradation and attracted the favour of academic institutions, large pharmaceutical enterprises, and biotechnology companies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36120561",
          "text": "PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway.",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970635",
          "text": "PROTACs (proteolysis targeting chimeras) are an emerging class of promising therapeutic modalities that degrade intracellular protein targets by hijacking the cellular ubiquitin-proteasome system.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30706727",
          "text": "y reducing or eliminating disease-causing proteins. PROTACs are bifunctional molecules that consist of a target protein ligand, a linker and an E3 lig",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30706727",
        "http://www.ncbi.nlm.nih.gov/pubmed/30631068",
        "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
        "http://www.ncbi.nlm.nih.gov/pubmed/33959589",
        "http://www.ncbi.nlm.nih.gov/pubmed/33970635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35589670",
        "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
        "http://www.ncbi.nlm.nih.gov/pubmed/35471699",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
        "http://www.ncbi.nlm.nih.gov/pubmed/36232374"
      ]
    },
    {
      "id": "62008022c9dfcb9c0900001b",
      "type": "list",
      "body": "Which variables are included in the ALBI grade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
          "text": "RESULTS\nALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type.",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies.",
          "offsetInBeginSection": 2136,
          "offsetInEndSection": 2359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
          "text": "Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 825,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "BACKGROUND & AIMS\nThe albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
          "text": "BACKGROUND\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
          "text": "BI grade provided distinct survival curves for C-P B (P = .02), BCLC B (P = .001), and BCLC C (P = .02). When substratified by BCLC stage, ALBI grade ",
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1391,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28295594",
          "text": "This study aimed to elucidate the application of ALBI grade in baseline and sorafenib-end in advanced HCC patients who received sorafenib.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
          "text": "Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
        "http://www.ncbi.nlm.nih.gov/pubmed/33346079",
        "http://www.ncbi.nlm.nih.gov/pubmed/30842180",
        "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
        "http://www.ncbi.nlm.nih.gov/pubmed/27038686",
        "http://www.ncbi.nlm.nih.gov/pubmed/35211856",
        "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
        "http://www.ncbi.nlm.nih.gov/pubmed/33442542",
        "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
        "http://www.ncbi.nlm.nih.gov/pubmed/36411535"
      ]
    },
    {
      "id": "64240f33690f196b51000049",
      "type": "list",
      "body": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
          "text": "fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
          "text": "ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
          "text": "ive and no relapse was observed.\n\n\nConclusions and relevance\nGS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces",
          "offsetInBeginSection": 1427,
          "offsetInEndSection": 1577,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
          "text": "ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
          "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 736,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458025",
          "text": "s slightly better in specific pathogen-free cats treated with NP7 and NP8 with fCpG-ODNs. However, immune tolerance was suggested to be induced by the",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 771,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8588340",
          "text": "Feline infectious peritonitis (FIP) virus antigen was demonstrated after methanol, ethanol or formalin fixation in paraffin-embedded tissues by means of monoclonal and polyclonal antibodies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33644160",
          "text": "For the treatment of FIP, several effective antivirals were recently reported, but many of these are not available for practical use.",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
          "text": "This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate molnupiravir as a potentially safe and effective therapy for FIP.",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1292,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36015002",
          "text": " cats that presented with these laboratory changes. This study shows that PI is beneficial in the treatment of FIP, and more studies are needed to est",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1379,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
        "http://www.ncbi.nlm.nih.gov/pubmed/27264736",
        "http://www.ncbi.nlm.nih.gov/pubmed/33138721",
        "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
        "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
        "http://www.ncbi.nlm.nih.gov/pubmed/9637307",
        "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
        "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
        "http://www.ncbi.nlm.nih.gov/pubmed/24458025",
        "http://www.ncbi.nlm.nih.gov/pubmed/19482534"
      ]
    },
    {
      "id": "6428da98690f196b51000053",
      "type": "yesno",
      "body": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
          "text": "million cases have occurred worldwide as of June 16, 2020. However, it is important to distinguish COVID-19 from other respiratory infectious diseases",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 238,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
          "text": " hospitalized patients with other viral pneumonias such as influenza is unknown.\n\n\nObjectives\nTo assess the incidence of venous and arterial thromboti",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
          "text": "n most\u00a0other contagious respiratory illnesses. The\u00a0mechanisms underlying this difference remain unclear.\n\n\nMETHODS\nWe compared the immunological lands",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32832306",
          "text": "COVID-19) are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 pandemic is caused by a novel virus - severe a",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
          "text": "Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
          "text": "ose with dengue or influenza, adjusting for age, subregion, and days from illness onset to presentation for clinical care. Among 13,431 participants, ",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 847,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
          "text": "other respiratory viral infections, such as Influenza, has not hitherto been extensively studied. We aimed to compare the prognostic value of NLR in C",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33615750",
          "text": "However, as the treatments and prognoses of COVID-19 and influenza are different, it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics.",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 483,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
          "text": "evere respiratory distress, such as influenza virus infection, are not fully understood. Here we addressed this by developing a prospective observatio",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 340,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
        "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
        "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
        "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
        "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
        "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
        "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
        "http://www.ncbi.nlm.nih.gov/pubmed/32511543",
        "http://www.ncbi.nlm.nih.gov/pubmed/33901185",
        "http://www.ncbi.nlm.nih.gov/pubmed/32881022"
      ]
    },
    {
      "id": "6415c8f1690f196b51000017",
      "type": "factoid",
      "body": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
          "text": "used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have b",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "rubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast cancer. In addition to standard eligibility criteria, patients with c",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
          "text": "her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 240,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
          "text": "While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
          "text": "apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
          "text": "re among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11129728",
          "text": "The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "We conclude that the combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activity.",
          "offsetInBeginSection": 1939,
          "offsetInEndSection": 2111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
          "text": "BACKGROUND\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9516602",
          "text": "l) and epirubicin, the 4'-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven metastatic ",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 236,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
        "http://www.ncbi.nlm.nih.gov/pubmed/9516602",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865686",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970750",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970739",
        "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
        "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
        "http://www.ncbi.nlm.nih.gov/pubmed/32365878",
        "http://www.ncbi.nlm.nih.gov/pubmed/10511918",
        "http://www.ncbi.nlm.nih.gov/pubmed/11346678"
      ]
    },
    {
      "id": "63eeec79f36125a426000006",
      "type": "factoid",
      "body": "Talquetamab was developed for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
          "text": "cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 231,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
          "text": "OBJECTIVES\nThe objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing s",
          "offsetInBeginSection": 1620,
          "offsetInEndSection": 1770,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25949982",
          "text": "ocrinology unit with excessive sweating. We started methimazole for Graves' disease. Without any additional immunosuppressive treatment, at week 12 of",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
          "text": "In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1011,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
          "text": "It was indicated that danaparoid sodium was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.",
          "offsetInBeginSection": 887,
          "offsetInEndSection": 1074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
          "text": "as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of pa",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36462062",
        "http://www.ncbi.nlm.nih.gov/pubmed/18673132",
        "http://www.ncbi.nlm.nih.gov/pubmed/15866475",
        "http://www.ncbi.nlm.nih.gov/pubmed/26179525",
        "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
        "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
        "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
        "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
        "http://www.ncbi.nlm.nih.gov/pubmed/8100702"
      ]
    },
    {
      "id": "642321a5690f196b51000047",
      "type": "summary",
      "body": "Please summarize Feline Spongiform Encephalopathy(FSE",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11206004",
          "text": "Feline Spongiform Encephalopathy (FSE) is a related disorder in domestic cats.",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11206004"
      ]
    },
    {
      "id": "6428d7da690f196b51000050",
      "type": "yesno",
      "body": "Can untranslated regions (UTRs) regulate gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
          "text": " (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
          "text": "Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
          "text": "5' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
          "text": "3' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
          "text": "n of gene expression; however, the exact sequence features contributing to gene regulation are not yet fully understood. In this study, we report the ",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
          "text": "The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
          "text": "Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
          "text": "gene expression can be regulated by the differential use of alternative untranslated regions. Tissue-specific expression of transcripts that have different untranslated regions (UTRs) can control protein expression",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 363,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29165424",
          "text": "These structures may regulate cap-dependent translation initiation through helicase-mediated remodelling of RNA structures and higher-order RNA interactions, as well as cap-independent translation initiation through internal ribosome entry sites (IRESs), mRNA modifications and other specialized translation pathways.",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 646,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
        "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
        "http://www.ncbi.nlm.nih.gov/pubmed/29165424",
        "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
        "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
        "http://www.ncbi.nlm.nih.gov/pubmed/16430990",
        "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
        "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
        "http://www.ncbi.nlm.nih.gov/pubmed/20563548"
      ]
    },
    {
      "id": "63f9cbb433942b094c00000c",
      "type": "yesno",
      "body": "Is alternative splicing associated with heart disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": "assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 903,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
          "text": "In humans, cardiac mRNA splicing is involved in the pathophysiology of heart failure.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
          "text": "In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
          "text": "Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 977,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561820",
          "text": " from individual genes; however, aberrant mRNA splicing is associated with various conditions, including heart disease. A recent study provides new me",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "e been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about ",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 363,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "Several genes that have splicing regulated by GATA4 have functional consequences and many are associated with dilated cardiomyopathy, suggesting a novel role for GATA4 in achieving the necessary cardiac proteome in normal and stress-responsive conditions.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573439",
          "text": "The aim of this review is to provide a brief insight into some of the available findings on the role of alternative splicing in cardiovascular disease, with a focus on atherosclerosis, myocardial infarction, heart failure, dilated cardiomyopathy and circular RNAs in myocardial infarction.",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1355,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
          "text": "However, mechanisms that maintain triadin isoform composition in the heart remain elusive.",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 678,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29186814",
          "text": "Alteration of Cav1.2 channel function has been implicated in multiple cardiovascular diseases, such as hypertension and cardiac hypertrophy.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 268,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22561820",
        "http://www.ncbi.nlm.nih.gov/pubmed/34573439",
        "http://www.ncbi.nlm.nih.gov/pubmed/29186814",
        "http://www.ncbi.nlm.nih.gov/pubmed/35862102",
        "http://www.ncbi.nlm.nih.gov/pubmed/34273561",
        "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
        "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
        "http://www.ncbi.nlm.nih.gov/pubmed/30468920"
      ]
    },
    {
      "id": "61fa941ec9dfcb9c09000005",
      "type": "yesno",
      "body": "Should Intepirdine be used for Alzheimer's disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
          "text": "cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown ",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1164,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29848076"
      ]
    },
    {
      "id": "6422e2f1690f196b51000043",
      "type": "factoid",
      "body": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
          "text": "Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs \u223c30-fold in the clinic (1).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
          "text": "One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099004",
          "text": "Herein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor.",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "PA:LFn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 \u00b1 19.1%, 36.4 \u00b1 1.8% and 22.9 \u00b1 6.9% (respectively) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.",
          "offsetInBeginSection": 2003,
          "offsetInEndSection": 2248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
          "text": "eptor (ASGPR) can serve as potent targeting moieties for hepatocellular carcinoma (HCC) cells. However, efficient targeting to HCC via galactose moiet",
          "offsetInBeginSection": 209,
          "offsetInEndSection": 359,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": "GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797690",
          "text": "ependent localization of ASOs delivered by a modified treatment of suspension cells. Our results show that in macrophages, the uptake rate of PS-ASOs ",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1307,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "In conclusion, these siRNA conjugates have the potential for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells for efficient gene silencing in vivo.",
          "offsetInBeginSection": 1273,
          "offsetInEndSection": 1441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
          "text": "ne glycol) (M6P-PEG) for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells (HSCs), respectively. These siRNA conjugates were purif",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 445,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "Atx complex formation with ASOs or siRNA was achieved via the in-frame fusion of either Saccharomyces cerevisiae GAL4 or Homo sapien sapien PKR (respectively) to a truncation of Atx lethal factor (LFn), which were used with Atx protective antigen (PA).",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 727,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
        "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
        "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
        "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797690",
        "http://www.ncbi.nlm.nih.gov/pubmed/22970170",
        "http://www.ncbi.nlm.nih.gov/pubmed/20964335",
        "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
        "http://www.ncbi.nlm.nih.gov/pubmed/31099004"
      ]
    },
    {
      "id": "64299fa957b1c7a315000002",
      "type": "summary",
      "body": "What is rebound COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
          "text": "Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
          "text": " infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
          "text": "o its end, will COVID-19 return again in what is known as a second rebound of the pandemic? In this work, we developed a predictive model that can est",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 594,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Importance\nRecent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
          "text": "till under global pandemic. China is facing the risks of importation and local rebound of COVID-19. Under the circumstances, preparations for medical ",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
          "text": "00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\n\n\nResults\nArea-level socio",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 992,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Main Outcomes and Measures\nThree types of COVID-19 rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were examined.",
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
        "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
        "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
        "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
        "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
        "http://www.ncbi.nlm.nih.gov/pubmed/36181334"
      ]
    },
    {
      "id": "6432fb1957b1c7a31500001e",
      "type": "list",
      "body": "What clinical applications is Zanubrutinib approved for in the United States?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
          "text": "ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 513,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ",
          "offsetInBeginSection": 1223,
          "offsetInEndSection": 1373,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
          "text": "ed accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop ",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875923",
          "text": "n's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochr",
          "offsetInBeginSection": 49,
          "offsetInEndSection": 199,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
          "text": "BTK) approved for the treatment of Waldenstr\u00f6m's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "Zanubrutinib, a second-generation BTK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 118 patients from two multicenter clinical trials, BGB-3111-AU-003 and BGB-3111-206.",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 549,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 890,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.",
          "offsetInBeginSection": 1833,
          "offsetInEndSection": 2090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Results of clinical studies on zanubrutinib treatment appear promising in patients with several types of B-cell malignancies, including mantle cell lymphoma (MCL), Waldenstr\u00f6m macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia, and small lymphocytic lymphoma.",
          "offsetInBeginSection": 2590,
          "offsetInEndSection": 2881,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34558376",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/32861286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34051727",
        "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35680835",
        "http://www.ncbi.nlm.nih.gov/pubmed/36252483",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/31875923",
        "http://www.ncbi.nlm.nih.gov/pubmed/35770040"
      ]
    },
    {
      "id": "61f7cb37882a024a10000029",
      "type": "yesno",
      "body": "Is rilonacept effective for pericarditis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
          "text": "RHAPSODY (rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1\u03b1 and -\u03b2 cytokine trap) in recurrent pericarditis.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 383,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
          "text": "-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1\u03b1 and interleukin-1\u03b2 cytokine t",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
          "text": "It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
          "text": "Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
          "text": "rapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.\n\n\nTRIAL REGISTRATION NUMBER\nNCT03737110.",
          "offsetInBeginSection": 1909,
          "offsetInEndSection": 2059,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33882846",
          "text": " and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1\u03b1/IL-1\u03b2 cytokine trap) to treat RP.\n\n\nMETHODS",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 301,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
          "text": "In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.",
          "offsetInBeginSection": 2149,
          "offsetInEndSection": 2353,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
          "text": "In the Phase III trial, rilonacept was associated with a lower risk of recurrence, more persistent clinical response, and higher amount of days with no or minimal pericarditis symptoms, compared with placebo.",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 797,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
          "text": "It is yet to be determined whether rilonacept would be an effective treatment for other chronic inflammatory conditions such as gout, familial Mediterranean fever and systemic juvenile idiopathic arthritis.",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639340",
          "text": "Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurrent pericarditis.",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 780,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
        "http://www.ncbi.nlm.nih.gov/pubmed/33229362",
        "http://www.ncbi.nlm.nih.gov/pubmed/34459270",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
        "http://www.ncbi.nlm.nih.gov/pubmed/35639340",
        "http://www.ncbi.nlm.nih.gov/pubmed/19649332",
        "http://www.ncbi.nlm.nih.gov/pubmed/33737453",
        "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
        "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
        "http://www.ncbi.nlm.nih.gov/pubmed/33882846"
      ]
    },
    {
      "id": "6413712a201352f04a00003e",
      "type": "list",
      "body": "The 1p19q co-deletion is associated with what types of tumors?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
          "text": "INTRODUCTION\nAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
          "text": "Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "ty and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative me",
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1106,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.",
          "offsetInBeginSection": 871,
          "offsetInEndSection": 1110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
          "text": "Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.",
          "offsetInBeginSection": 1342,
          "offsetInEndSection": 1558,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344797",
          "text": "However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and vincristine (PCV).",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1686,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "text": "H results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098). Gliomas positive for 1p19q co-deletions did not have other frequently recurren",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 697,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
          "text": "uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette",
          "offsetInBeginSection": 1462,
          "offsetInEndSection": 1612,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29704080",
          "text": "BACKGROUND\nThe purpose of this study is to map spatial metabolite differences across three molecular subgroups of glial tumors, defined by the IDH1/2 mutation and 1p19q-co-deletion, using magnetic resonance spectroscopy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18565359",
        "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
        "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
        "http://www.ncbi.nlm.nih.gov/pubmed/32005184",
        "http://www.ncbi.nlm.nih.gov/pubmed/20035368",
        "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
        "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
        "http://www.ncbi.nlm.nih.gov/pubmed/30656222",
        "http://www.ncbi.nlm.nih.gov/pubmed/29704080",
        "http://www.ncbi.nlm.nih.gov/pubmed/21653654"
      ]
    },
    {
      "id": "6429ad3857b1c7a315000003",
      "type": "factoid",
      "body": "The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
          "text": "e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 582,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
          "text": "This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21471966",
          "text": "The developmental regulation of this process has been extensively investigated in mice, where the X chromosome of paternal origin (Xp) is silenced during early embryogenesis owing to imprinted expression of the regulatory RNA, Xist (X-inactive specific transcript).",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 388,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
        "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
        "http://www.ncbi.nlm.nih.gov/pubmed/21471966"
      ]
    },
    {
      "id": "63f92fd033942b094c00000b",
      "type": "summary",
      "body": "What are microexons?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "text": "The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
          "text": "Microexons are small sized (\u226451\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
          "text": "However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\u00a0nt, require specialized computational workflows.",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
          "text": "ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
          "text": "Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
          "text": "BACKGROUND\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
          "text": "Exons with a length \u2264 30 nt are defined as microexons that are unique in identification.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526869",
          "text": "(2018) uncover novel mechanisms by which the cell regulates splicing of cryptic splice sites and microexons.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
          "text": "expression or activity of splicing factors (SFs). Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserve",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 223,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "Microexons (\u226427 nt) play critical roles in nervous system development and function but create unique challenges for the splicing machinery.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
        "http://www.ncbi.nlm.nih.gov/pubmed/20659428",
        "http://www.ncbi.nlm.nih.gov/pubmed/35858306",
        "http://www.ncbi.nlm.nih.gov/pubmed/35089784",
        "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
        "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
        "http://www.ncbi.nlm.nih.gov/pubmed/31999954",
        "http://www.ncbi.nlm.nih.gov/pubmed/35145097",
        "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
        "http://www.ncbi.nlm.nih.gov/pubmed/25525873"
      ]
    },
    {
      "id": "64041f38201352f04a00001f",
      "type": "yesno",
      "body": "Is tebentafusp effective for uveal melanoma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 334,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
          "text": "PURPOSE\nAnti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
          "text": "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
          "text": "cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors ",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1293,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
          "text": "Data showing a proven overall survival benefit with a systemic treatment are lacking.",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20375921",
          "text": "n the remaining case. Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to pati",
          "offsetInBeginSection": 1488,
          "offsetInEndSection": 1638,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
          "text": " people of Asian or Pacific Island ancestry. While uveal melanoma is most common in Caucasian populations, other HLA-restricted cancer therapeutics ar",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
          "text": "RESULTS\nTebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.",
          "offsetInBeginSection": 705,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
          "text": "CONCLUSIONS\nTreatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.",
          "offsetInBeginSection": 1945,
          "offsetInEndSection": 2112,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
        "http://www.ncbi.nlm.nih.gov/pubmed/36442912",
        "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
        "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
        "http://www.ncbi.nlm.nih.gov/pubmed/1589858",
        "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
        "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
        "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
        "http://www.ncbi.nlm.nih.gov/pubmed/36102132"
      ]
    },
    {
      "id": "6426bb49690f196b5100004d",
      "type": "summary",
      "body": "What is the Fenton reaction",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26948406",
          "text": "m 5.0 nM to 1.0 \u03bcM with a detection limit of 2.4 nM. Because of the rapid kinetics of Fenton reaction and high specificity for H2O2, the proposed meth",
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1278,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
          "text": "INTRODUCTION\nFenton reaction is the main source of free radicals in biological systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
          "text": "The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradation of biologically and chemically recalcitrant organic compounds in surface waters at circum-neutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
          "text": "Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
          "text": "Fenton reaction is widely used for hazardous pollutant degradation. Reducing agents (RAs) have been proven to be efficient in promoting the generation",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
          "text": "s that FeII-counteranion complexes are the real catalyst for fast aqueous Fenton reactions. In addition, we found that the Fenton oxidation mediated b",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 858,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780882",
          "text": "It has been well recognized that the Fenton reaction requires a rigorous pH control and suffers from the fast self-degradation of H2O2.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395600",
          "text": " in aqueous environments. The Fenton reaction, as an effective organic pollution treatment technology, is particularly suitable for the treatment of a",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30991337",
          "text": "Bimetallic Fe/Al system for the Fenton reaction in water involves both surface-mediated and aqueous-phase reactions.",
          "offsetInBeginSection": 1221,
          "offsetInEndSection": 1337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36080218",
          "text": "The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reactive and highly toxic to living cells.",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26948406",
        "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
        "http://www.ncbi.nlm.nih.gov/pubmed/30991337",
        "http://www.ncbi.nlm.nih.gov/pubmed/15963810",
        "http://www.ncbi.nlm.nih.gov/pubmed/35780882",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
        "http://www.ncbi.nlm.nih.gov/pubmed/35098712",
        "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
        "http://www.ncbi.nlm.nih.gov/pubmed/32596808",
        "http://www.ncbi.nlm.nih.gov/pubmed/31259456"
      ]
    }
  ]
}